Article Text

Download PDFPDF
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era
  1. M H Williams1,
  2. C Das2,
  3. C E Handler2,
  4. M R Akram1,
  5. J Davar1,
  6. C P Denton2,
  7. C J Smith3,
  8. C M Black2,
  9. J G Coghlan1
  1. 1Department of Cardiology, Royal Free Hospital, London, UK
  2. 2Department of Rheumatology, Royal Free Hospital, London, UK
  3. 3Department of Primary Care and Population Sciences, Royal Free & University College Medical School, London, UK
  1. Correspondence to:
    Dr John G Coghlan
    Department of Cardiology, Royal Free Hospital, Pond Street, London NW3 2QG, UK; gerry.coghlan{at}royalfree.nhs.uk

Footnotes

  • Published Online First 9 December 2005

  • None of the authors have any financial association that can give conflict of interest. However, Drs Coghlan and Denton and Professor Black have unrestricted research grants from and have acted as advisors to pharmaceutical companies including Actelion, Genzyme and Schering. They have been investigators in clinical trials sponsored by these companies.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Published Online First 9 December 2005

  • None of the authors have any financial association that can give conflict of interest. However, Drs Coghlan and Denton and Professor Black have unrestricted research grants from and have acted as advisors to pharmaceutical companies including Actelion, Genzyme and Schering. They have been investigators in clinical trials sponsored by these companies.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.